Active Ingredient History
Nadroparin is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by Sanofi-Synthélabo. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Kidney Injury (Phase 4)
Brain Ischemia (Phase 2)
Cardiopulmonary Bypass (Phase 4)
Critical Illness (Phase 4)
Ischemic Stroke (Phase 4)
Kidney Failure, Chronic (Phase 4)
Liver Cirrhosis (Phase 4)
Lung Neoplasms (Phase 3)
May-Thurner Syndrome (Phase 3)
Neoplasms (Phase 3)
Obesity, Morbid (Phase 4)
Pregnancy Complications (Phase 3)
Pulmonary Embolism (Phase 4)
Subarachnoid Hemorrhage (Phase 2)
Thromboembolism (Phase 4)
Thrombosis (Phase 4)
Upper Extremity Deep Vein Thrombosis (Phase 3)
Vascular Diseases (Phase 4)
Venous Thromboembolism (Phase 3)
Venous Thrombosis (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
